Oruka Therapeutics, INC Schedule 13G passive stakes

Several Venrock-affiliated entities and individuals have reported a combined beneficial ownership of 7.4% in Oruka Therapeutics, Inc. common stock as of June 30, 2026.

RTW Investments, LP and Roderick Wong, M.D. have filed a Schedule 13G, confirming beneficial ownership of 3,139,030 shares, representing 5.2% of Oruka Therapeutics, Inc. common stock.

Viking Global Investors filed an amended Schedule 13G to reflect the retirement of David C. Ott from its reporting group.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Oruka Therapeutics Inc. following an internal realignment.

RTW Investments, LP and Roderick Wong, M.D. have reported a beneficial ownership of 4.3% in Oruka Therapeutics, Inc., as per their Schedule 13G/A filing.

Deep Track Capital and affiliated entities disclose an updated beneficial ownership of Oruka Therapeutics, Inc. common stock, collectively holding approximately 8.93%.

The Vanguard Group has reported a 5.06% beneficial ownership stake in Oruka Therapeutics Inc. as of December 31, 2025.

BlackRock, Inc. has reported a 6.6% beneficial ownership stake in Oruka Therapeutics, Inc., holding 3,175,483 shares of common stock as of December 31, 2025.

A group of Venrock Healthcare Capital Partners entities and individuals disclosed a continued 9.9% beneficial ownership stake in Oruka Therapeutics, Inc. common stock.

BlackRock, Inc. has reported a beneficial ownership of 4.5% in Oruka Therapeutics, Inc. common stock, indicating a passive investment below the 5% threshold.

Viking Global Investors and its affiliates have reported a 5.5% beneficial ownership stake in Oruka Therapeutics, Inc., totaling 2,666,690 shares.

BlackRock, Inc. has filed a Schedule 13G, revealing a beneficial ownership of 5.3% of Oruka Therapeutics, Inc.'s common stock as of June 30, 2025.

RTW Investments, LP and its Managing Partner, Roderick Wong, M.D., have disclosed a beneficial ownership of 5.2% of Oruka Therapeutics, Inc.'s Common Stock.

Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd. and David Kroin, has disclosed a beneficial ownership of 5.07% in Oruka Therapeutics, Inc.'s common stock.

Venrock Healthcare Capital Partners and its affiliated entities have filed an amended Schedule 13G, confirming their continued beneficial ownership of 11.1% of Oruka Therapeutics, Inc.'s common stock.